Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 5 | 2015 | 40 | 1.550 |
Why?
|
| Managed Care Programs | 6 | 2017 | 356 | 1.210 |
Why?
|
| Health Expenditures | 3 | 2014 | 81 | 0.950 |
Why?
|
| Diverticulitis, Colonic | 2 | 2014 | 8 | 0.940 |
Why?
|
| Emergency Service, Hospital | 4 | 2021 | 357 | 0.670 |
Why?
|
| Middle Aged | 20 | 2021 | 8073 | 0.650 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2018 | 42 | 0.610 |
Why?
|
| Febrile Neutropenia | 1 | 2017 | 3 | 0.600 |
Why?
|
| Algorithms | 2 | 2020 | 235 | 0.600 |
Why?
|
| Data Collection | 3 | 2014 | 276 | 0.600 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2014 | 70 | 0.570 |
Why?
|
| Antirheumatic Agents | 3 | 2015 | 12 | 0.570 |
Why?
|
| Retrospective Studies | 12 | 2021 | 2498 | 0.560 |
Why?
|
| Asthma | 2 | 2016 | 302 | 0.550 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2015 | 6 | 0.540 |
Why?
|
| Aged | 17 | 2021 | 6258 | 0.520 |
Why?
|
| Male | 19 | 2021 | 10173 | 0.520 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 205 | 0.510 |
Why?
|
| Female | 19 | 2021 | 12838 | 0.510 |
Why?
|
| Diverticulitis | 1 | 2014 | 2 | 0.500 |
Why?
|
| Humans | 22 | 2021 | 18058 | 0.480 |
Why?
|
| Inpatients | 1 | 2014 | 79 | 0.480 |
Why?
|
| Outpatients | 1 | 2014 | 113 | 0.470 |
Why?
|
| Electronic Health Records | 3 | 2020 | 734 | 0.470 |
Why?
|
| Consumer Behavior | 2 | 2004 | 31 | 0.470 |
Why?
|
| Health Care Costs | 1 | 2015 | 253 | 0.450 |
Why?
|
| Mental Health | 1 | 2014 | 166 | 0.440 |
Why?
|
| Young Adult | 8 | 2015 | 2479 | 0.430 |
Why?
|
| Ambulatory Care | 1 | 2014 | 274 | 0.430 |
Why?
|
| Self Report | 1 | 2014 | 252 | 0.420 |
Why?
|
| Adolescent | 9 | 2015 | 3714 | 0.420 |
Why?
|
| Adult | 12 | 2016 | 7696 | 0.390 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 454 | 0.380 |
Why?
|
| Acute Coronary Syndrome | 2 | 2021 | 17 | 0.370 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 397 | 0.370 |
Why?
|
| California | 9 | 2019 | 2327 | 0.360 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 1023 | 0.350 |
Why?
|
| Acute Disease | 3 | 2014 | 138 | 0.340 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 1956 | 0.340 |
Why?
|
| Comorbidity | 4 | 2015 | 618 | 0.330 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2019 | 60 | 0.330 |
Why?
|
| Cohort Studies | 6 | 2020 | 2631 | 0.290 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 264 | 0.260 |
Why?
|
| United States | 6 | 2015 | 4119 | 0.250 |
Why?
|
| Drug Industry | 1 | 2004 | 3 | 0.240 |
Why?
|
| Drug Information Services | 1 | 2004 | 3 | 0.240 |
Why?
|
| Formularies as Topic | 1 | 2004 | 2 | 0.240 |
Why?
|
| Leukocytosis | 2 | 2014 | 5 | 0.240 |
Why?
|
| Advertising as Topic | 1 | 2004 | 25 | 0.240 |
Why?
|
| Abdominal Pain | 2 | 2014 | 15 | 0.240 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2004 | 28 | 0.230 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 350 | 0.230 |
Why?
|
| Fever | 2 | 2014 | 60 | 0.230 |
Why?
|
| Treatment Outcome | 3 | 2018 | 1259 | 0.230 |
Why?
|
| Critical Pathways | 1 | 2021 | 11 | 0.190 |
Why?
|
| Odds Ratio | 4 | 2015 | 692 | 0.190 |
Why?
|
| Sex Factors | 3 | 2021 | 634 | 0.190 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2020 | 2 | 0.180 |
Why?
|
| Tonsillar Neoplasms | 1 | 2020 | 2 | 0.180 |
Why?
|
| Robotic Surgical Procedures | 1 | 2020 | 6 | 0.180 |
Why?
|
| Exercise Test | 1 | 2020 | 43 | 0.180 |
Why?
|
| Urinary Bladder | 1 | 2019 | 11 | 0.180 |
Why?
|
| Hospitalization | 2 | 2017 | 813 | 0.170 |
Why?
|
| BCG Vaccine | 1 | 2019 | 6 | 0.170 |
Why?
|
| Adjuvants, Immunologic | 1 | 2019 | 15 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 55 | 0.170 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 57 | 0.170 |
Why?
|
| Recurrence | 2 | 2016 | 186 | 0.160 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 613 | 0.160 |
Why?
|
| Incidence | 3 | 2017 | 1297 | 0.160 |
Why?
|
| Risk Assessment | 2 | 2021 | 1137 | 0.160 |
Why?
|
| Disease Progression | 2 | 2016 | 255 | 0.160 |
Why?
|
| Mastectomy, Segmental | 1 | 2018 | 23 | 0.160 |
Why?
|
| Mastectomy | 1 | 2018 | 36 | 0.160 |
Why?
|
| Health Status Disparities | 1 | 2019 | 154 | 0.150 |
Why?
|
| Logistic Models | 3 | 2015 | 953 | 0.150 |
Why?
|
| Comparative Effectiveness Research | 1 | 2018 | 72 | 0.150 |
Why?
|
| Blood Cells | 1 | 2016 | 4 | 0.140 |
Why?
|
| Eosinophils | 1 | 2016 | 9 | 0.140 |
Why?
|
| Quality of Health Care | 1 | 2019 | 346 | 0.140 |
Why?
|
| Age Factors | 2 | 2019 | 945 | 0.140 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2019 | 552 | 0.140 |
Why?
|
| Population Surveillance | 2 | 2015 | 270 | 0.140 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 595 | 0.130 |
Why?
|
| Registries | 1 | 2018 | 486 | 0.130 |
Why?
|
| Etanercept | 1 | 2015 | 3 | 0.130 |
Why?
|
| Medication Adherence | 2 | 2015 | 255 | 0.130 |
Why?
|
| Adalimumab | 1 | 2015 | 4 | 0.130 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 87 | 0.130 |
Why?
|
| Hip Fractures | 1 | 2015 | 70 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2014 | 235 | 0.120 |
Why?
|
| Patient Preference | 1 | 2014 | 49 | 0.120 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2013 | 3 | 0.110 |
Why?
|
| Bupropion | 1 | 2013 | 11 | 0.110 |
Why?
|
| Quinoxalines | 1 | 2013 | 12 | 0.110 |
Why?
|
| Sentinel Surveillance | 1 | 2013 | 14 | 0.110 |
Why?
|
| Nicotinic Agonists | 1 | 2013 | 26 | 0.110 |
Why?
|
| Benzazepines | 1 | 2013 | 24 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 177 | 0.110 |
Why?
|
| Economics, Pharmaceutical | 1 | 2012 | 3 | 0.110 |
Why?
|
| Home Care Agencies | 1 | 2012 | 3 | 0.110 |
Why?
|
| Abscess | 1 | 2012 | 6 | 0.110 |
Why?
|
| Prognosis | 1 | 2014 | 619 | 0.110 |
Why?
|
| Continental Population Groups | 1 | 2014 | 317 | 0.110 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2013 | 113 | 0.110 |
Why?
|
| Drug Costs | 1 | 2012 | 39 | 0.110 |
Why?
|
| Office Visits | 1 | 2012 | 85 | 0.100 |
Why?
|
| Ethnic Groups | 1 | 2015 | 504 | 0.100 |
Why?
|
| Smoking Cessation | 1 | 2013 | 198 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2012 | 184 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 667 | 0.090 |
Why?
|
| Risk Factors | 2 | 2014 | 3394 | 0.090 |
Why?
|
| United States Food and Drug Administration | 2 | 2013 | 34 | 0.090 |
Why?
|
| Time Factors | 1 | 2012 | 1114 | 0.080 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 330 | 0.080 |
Why?
|
| Periodicals as Topic | 1 | 2004 | 14 | 0.060 |
Why?
|
| Texas | 1 | 2004 | 33 | 0.060 |
Why?
|
| Hispanic Americans | 2 | 2019 | 431 | 0.060 |
Why?
|
| European Continental Ancestry Group | 2 | 2019 | 559 | 0.060 |
Why?
|
| Guidelines as Topic | 1 | 2004 | 42 | 0.060 |
Why?
|
| Attitude | 1 | 2004 | 34 | 0.060 |
Why?
|
| African Americans | 2 | 2019 | 485 | 0.060 |
Why?
|
| Health Services Research | 1 | 2004 | 271 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 1255 | 0.050 |
Why?
|
| Markov Chains | 1 | 2020 | 26 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2004 | 1309 | 0.040 |
Why?
|
| Administration, Intravesical | 1 | 2019 | 2 | 0.040 |
Why?
|
| Natural Language Processing | 1 | 2020 | 53 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 83 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 318 | 0.040 |
Why?
|
| Cell Count | 1 | 2016 | 10 | 0.040 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2016 | 67 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 351 | 0.030 |
Why?
|
| Biomarkers | 1 | 2016 | 306 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 129 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 552 | 0.030 |
Why?
|
| Varenicline | 1 | 2013 | 13 | 0.030 |
Why?
|
| Tobacco Use Disorder | 1 | 2013 | 50 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2016 | 1294 | 0.030 |
Why?
|
| Health Behavior | 1 | 2015 | 379 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1164 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2013 | 157 | 0.030 |
Why?
|
| Medicaid | 1 | 2013 | 206 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 892 | 0.020 |
Why?
|
Concepts
(144)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(10)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->